Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Current Assets (2016 - 2025)

Dexcom (DXCM) has disclosed Current Assets for 16 consecutive years, with $4.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 6.23% to $4.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 billion, a 6.23% decrease, with the full-year FY2025 number at $4.0 billion, down 6.23% from a year prior.
  • Current Assets was $4.0 billion for Q4 2025 at Dexcom, down from $5.2 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $5.2 billion in Q3 2025 to a low of $3.4 billion in Q3 2022.
  • A 5-year average of $4.1 billion and a median of $3.9 billion in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 72.63% in 2021, then dropped 9.27% in 2024.
  • Dexcom's Current Assets stood at $3.7 billion in 2021, then decreased by 0.42% to $3.7 billion in 2022, then increased by 20.64% to $4.4 billion in 2023, then fell by 2.81% to $4.3 billion in 2024, then fell by 6.23% to $4.0 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Current Assets are $4.0 billion (Q4 2025), $5.2 billion (Q3 2025), and $4.6 billion (Q1 2025).